Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698 · View on ClinicalTrials.gov ↗
Study Summary
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Conditions Studied
Interventions
- DEVICE WATCHMAN device
Study Locations (20)
California
- Memorial Health Services — Fountain Valley
- Loma Linda University Health — Loma Linda
- Southern California Permanente Medical Group — Pasadena
- Sutter Valley Hospitals dba Sutter Institute for Medical Research — Sacramento
Florida
- JFK Medical Center Limited Partnership d/b/a HCA Florida JFK Hospital — Atlantis
- St. Vincent's Health System — Jacksonville
- Largo Medical Center, Inc. d/b/a HCA Florida Largo Medical Center — Largo
- The University of South Florida — Tampa
Idaho
- St Luke's Regional Medical Center, Ltd — Boise
- Kootenai Health Inc. — Coeur d'Alene
Illinois
- Northwestern University — Evanston
- Cardiovascular Medicine, PLLC and Unity Point Trinity Rock Island — Rock Island
Alabama
- Affinity Hospital dba Grandview Medical Center — Birmingham
Arkansas
- Arrhythmia Research Group — Jonesboro
Georgia
- Emory University — Atlanta
Indiana
- Community Health Network Inc. — Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2029-12-01 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05963698
The ClinicalTrials.gov registry entry for NCT05963698 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hamilton Health Sciences Corporation, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention — of which WATCHMAN device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05963698 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Florida, Idaho. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05963698 about?
NCT05963698 is a clinical study titled "The Fourth Left Atrial Appendage Occlusion Study". LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
What is the current status of trial NCT05963698?
This trial is currently recruiting. It is a NA study. The enrollment target is 4,000 participants. The study started on 2023-11-30. Estimated completion is 2029-12-01.
What conditions does trial NCT05963698 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05963698?
The interventions under investigation include: WATCHMAN device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05963698?
This trial is sponsored by Hamilton Health Sciences Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05963698 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.